Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-02: Low-dose Radiotherapy, Tirelizumab, and SOX for Gastric/Gastroesophageal Junction Adenocarcinoma
NCT06766578Phase 2Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Pathological complete response rate. Started Dec 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06766578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06766578.